A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation

NCT ID: NCT02822508

Last Updated: 2023-11-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

434 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate multiple doses of BLI801 Laxative for safety and efficacy versus placebo in adults experiencing non-idiopathic constipation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BLI801 Laxative (high dose)

BLI801 Laxative (high dose)

Group Type EXPERIMENTAL

BLI801 Laxative

Intervention Type DRUG

BLI801 oral laxative

BLI801 Laxative (mid dose)

BLI801 Laxative (mid dose)

Group Type EXPERIMENTAL

BLI801 Laxative

Intervention Type DRUG

BLI801 oral laxative

BLI801 Laxative (low dose)

BLI801 Laxative (low dose)

Group Type EXPERIMENTAL

BLI801 Laxative

Intervention Type DRUG

BLI801 oral laxative

BLI801 Placebo

BLI801 Placebo

Group Type PLACEBO_COMPARATOR

BLI801 Placebo

Intervention Type DRUG

BLI801 oral laxative placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BLI801 Laxative

BLI801 oral laxative

Intervention Type DRUG

BLI801 Placebo

BLI801 oral laxative placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects between the ages of \> 18 and \< 85 years
2. Constipated, defined by the following criteria: Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for the previous 4 weeks:

* Straining during \> 25% of defecations
* Lumpy or hard stools in \> 25% of defecations
* Sensation of incomplete evacuation for \> 25% of defecations
3. Receiving a stable maintenance opioid regimen.
4. If female, and of child-bearing potential, is using an acceptable form of birth control
5. Negative pregnancy test at screening (Visit 1), if applicable
6. In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria

1. Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon
2. Subjects who have had major surgery within 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1
3. Medical conditions associated with diarrhea, intermittent loose stools or constipation, which could confound the interpretation of the results, eg, fecal incontinence or irritable bowel syndrome. Subjects with irritable bowel syndrome (IBS) that has been previously diagnosed by a physician prior to initiation of the constipating therapy and that meets the following criteria, are excluded:

1. Absence of a structural or biochemical explanation for the abdominal pain symptom
2. At least 12 weeks during a period of 12 months, of abdominal discomfort or pain with at least 2 of the following 3 features:

i. Relieved with defecation, and/or ii. Onset associated with a change in frequency of stool, and/or iii. Onset associated with a change in form of stool.
4. Subjects diagnosed with chronic constipation prior to initiation of opioid treatment
5. Subjects taking laxatives (with the exception of fiber supplements), prokinetic agents or antidiarrheal drugs and refuse to discontinue these treatments from Visit 1 until after completion of Visit 5
6. Subjects who are pregnant or nursing, or intend to become pregnant during the study
7. Subjects of childbearing potential who refuse a pregnancy test
8. Subjects who are allergic to any BLI801 component
9. Subjects taking non-opioid medications or supplements known to cause constipation
10. Subjects with an active history of drug or alcohol abuse
11. Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
12. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
13. Subjects who have had a colonoscopy within 2 weeks of Visit 1 or are scheduled to have a colonoscopy during their participation in the study.
14. Subjects who withdraw consent at any time prior to completion of Visit 1 procedures
Minimum Eligible Age

18 Years

Maximum Eligible Age

84 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Braintree Laboratories

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John McGowan

Role: STUDY_DIRECTOR

Braintree Laboratories, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Braintree Research Site 43

Birmingham, Alabama, United States

Site Status

Braintree Research Site 30

Peoria, Arizona, United States

Site Status

Braintree Research Site 40

Phoenix, Arizona, United States

Site Status

Braintree Research Site 52

Phoenix, Arizona, United States

Site Status

Braintree Research Site 26

Phoenix, Arizona, United States

Site Status

Braintree Research Site 56

Fayetteville, Arkansas, United States

Site Status

Braintree Research Site 4

Little Rock, Arkansas, United States

Site Status

Braintree Research Site 51

Anaheim, California, United States

Site Status

Braintree Research Site 54

Fountain Valley, California, United States

Site Status

Braintree Research Site 8

Fresno, California, United States

Site Status

Braintree Research Site 71

Long Beach, California, United States

Site Status

Braintree Research Site 74

Oceanside, California, United States

Site Status

Braintree Research Site 59

Sacramento, California, United States

Site Status

Braintree Research Site 28

Sacramento, California, United States

Site Status

Braintree Research Site 68

Brooksville, Florida, United States

Site Status

Braintree Research Site 36

Fort Myers, Florida, United States

Site Status

Braintree Research Site 22

Homestead, Florida, United States

Site Status

Braintree Research Site 5

Jacksonville, Florida, United States

Site Status

Braintree Research Site 23

Jacksonville, Florida, United States

Site Status

Braintree Research Site 63

Miami, Florida, United States

Site Status

Braintree Research Site 29

Orlando, Florida, United States

Site Status

Braintree Research Site 65

Orlando, Florida, United States

Site Status

Braintree Research Site 13

Ormond Beach, Florida, United States

Site Status

Braintree Research Site 20

St. Petersburg, Florida, United States

Site Status

Braintree Research Site 39

St. Petersburg, Florida, United States

Site Status

Braintree Research Site 31

Tampa, Florida, United States

Site Status

Braintree Research Site 41

West Palm Beach, Florida, United States

Site Status

Braintree Research Site 57

Blue Ridge, Georgia, United States

Site Status

Braintree Research Site 48

Boise, Idaho, United States

Site Status

Braintree Research Site 50

Evansville, Indiana, United States

Site Status

Braintree Research Site 55

Lafayette, Indiana, United States

Site Status

Braintree Research Site 38

Wichita, Kansas, United States

Site Status

Braintree Research Site 64

Edgewood, Kentucky, United States

Site Status

Braintree Research Site 73

Lake Charles, Louisiana, United States

Site Status

Braintree Research Site 49

St Louis, Missouri, United States

Site Status

Braintree Research Site 19

Omaha, Nebraska, United States

Site Status

Braintree Research Site 21

Omaha, Nebraska, United States

Site Status

Braintree Research Site 69

Henderson, Nevada, United States

Site Status

Braintree Research Site 1

Las Vegas, Nevada, United States

Site Status

Braintree Research Site 44

Las Vegas, Nevada, United States

Site Status

Braintree Research Site 34

Las Vegas, Nevada, United States

Site Status

Braintree Research Site 7

Belvidere, New Jersey, United States

Site Status

Braintree Research Site 53

Trenton, New Jersey, United States

Site Status

Braintree Research Site 10

Albuquerque, New Mexico, United States

Site Status

Braintree Research Site 27

Brooklyn, New York, United States

Site Status

Braintree Research Site 25

Great Neck, New York, United States

Site Status

Braintree Research Site 61

Williamsville, New York, United States

Site Status

Braintree Research Site 45

Greensboro, North Carolina, United States

Site Status

Braintree Research Site 47

Winston-Salem, North Carolina, United States

Site Status

Braintree Research Site 2

Beavercreek, Ohio, United States

Site Status

Braintree Research Site 76

Cincinnati, Ohio, United States

Site Status

Braintree Research Site 3

Columbus, Ohio, United States

Site Status

Braintree Research Site 60

Columbus, Ohio, United States

Site Status

Braintree Research Site 14

Huber Heights, Ohio, United States

Site Status

Braintree Research Site 46

Oklahoma City, Oklahoma, United States

Site Status

Braintree Research Site 16

Oklahoma City, Oklahoma, United States

Site Status

Braintree Research Site 18

Lansdale, Pennsylvania, United States

Site Status

Braintree Research Site 75

Charleston, South Carolina, United States

Site Status

Braintree Research Site 17

Greer, South Carolina, United States

Site Status

Braintree Research Site 42

Myrtle Beach, South Carolina, United States

Site Status

Braintree Research Site 24

Spartanburg, South Carolina, United States

Site Status

Braintree Research Site 72

Spartanburg, South Carolina, United States

Site Status

Braintree Research Site 9

Summerville, South Carolina, United States

Site Status

Braintree Research Site 37

Chattanooga, Tennessee, United States

Site Status

Braintree Research Site 67

Tullahoma, Tennessee, United States

Site Status

Braintree Research Site 11

Austin, Texas, United States

Site Status

Braintree Research Site 33

Carrollton, Texas, United States

Site Status

Braintree Research Site 62

Channelview, Texas, United States

Site Status

Braintree Research Site 70

Houston, Texas, United States

Site Status

Braintree Research Site 35

Salt Lake City, Utah, United States

Site Status

Braintree Research Site 12

St. George, Utah, United States

Site Status

Braintree Research Site 66

West Jordan, Utah, United States

Site Status

Braintree Research Site 6

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BLI801-203

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.